title: Generic inhibition of amyloidogenic proteins by two naphthoquinone-tryptophan hybrid molecules.
abstract: Amyloid formation is associated with several human diseases including Alzheimer's disease (AD), Parkinson's disease, Type 2 Diabetes, and so forth, no disease modifying therapeutics are available for them. Because of the structural similarities between the amyloid species characterizing these diseases, (despite the lack of amino acid homology) it is believed that there might be a common mechanism of toxicity for these conditions. Thus, inhibition of amyloid formation could be a promising disease-modifying therapeutic strategy for them. Aromatic residues have been identified as crucial in formation and stabilization of amyloid structures. This finding was corroborated by high-resolution structural studies, theoretical analysis, and molecular dynamics simulations. Amongst the aromatic entities, tryptophan was found to possess the most amyloidogenic potential. We therefore postulate that targeting aromatic recognition interfaces by tryptophan could be a useful approach for inhibiting the formation of amyloids. Quinones are known as inhibitors of cellular metabolic pathways, to have anti- cancer, anti-viral and anti-bacterial properties and were shown to inhibit aggregation of several amyloidogenic proteins in vitro. We have previously described two quinone-tryptophan hybrids which are capable of inhibiting amyloid-beta, the protein associated with AD pathology, both in vitro and in vivo. Here we tested their generic properties and their ability to inhibit other amyloidogenic proteins including α-synuclein, islet amyloid polypeptide, lysozyme, calcitonin, and insulin. Both compounds showed efficient inhibition of all five proteins examined both by ThT fluorescence analysis and by electron microscope imaging. If verified in vivo, these small molecules could serve as leads for developing generic anti-amyloid drugs.
authors.affiliation: Department of Molecular Microbiology and Biotechnology, Tel-Aviv University, Tel-Aviv, Israel.
authors.forename: Roni
authors.initials: R
authors.lastname: Scherzer-Attali
authors.forename: Ronit
authors.initials: R
authors.lastname: Shaltiel-Karyo
authors.forename: Yonatan H
authors.initials: YH
authors.lastname: Adalist
authors.forename: Daniel
authors.initials: D
authors.lastname: Segal
authors.forename: Ehud
authors.initials: E
authors.lastname: Gazit
mesh_terms: D000544:Alzheimer Disease / Q000378:metabolism / Q000473:pathology; D058227:Amyloidogenic Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry*; D002116:Calcitonin / Q000737:chemistry; D006801:Humans; D007328:Insulin / Q000737:chemistry; D058228:Islet Amyloid Polypeptide / Q000737:chemistry; D009113:Muramidase / Q000737:chemistry; D009285:Naphthoquinones / Q000737:chemistry*; D014364:Tryptophan / Q000737:chemistry*; D051844:alpha-Synuclein / Q000737:chemistry
chemical_list: D058227:Amyloidogenic Proteins; D007328:Insulin; D058228:Islet Amyloid Polypeptide; D009285:Naphthoquinones; D051844:alpha-Synuclein; D014364:Tryptophan; D002116:Calcitonin; D009113:Muramidase